GlassScriptPhysician profile
Leonard V Cohen
NPI 1265427298
$61,416.12
in general payments reported to CMS, 2019-2025
61 companies · $2,107 in 2025
The $2,107 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,269 · 2020: $15K · 2021: $17K · 2022: $14K · 2023: $6,888 · 2024: $3,479 · 2025: $2,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,348 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,038 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,348.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,037.50 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,624.94 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Allergan, INC. | $14,776.47 | 2019-2022 | |
| Ucb, INC. | $1,716.89 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Eisai INC. | $1,673.09 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,082.79 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $867.93 | 2019-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $829.27 | 2019-2025 | |
| Emd Serono, INC. | $790.35 | 2020-2025 | Mavenclad |
| Pfizer INC. | $787.21 | 2023-2025 | |
| Biogen, INC. | $752.12 | 2019-2025 | Leqembi, Tysabri, Vumerity |
| Sk Life Science, INC. | $585.61 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $567.31 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $561.75 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Mdd US Operations, LLC | $532.43 | 2019-2025 | Apokyn |
| Acadia Pharmaceuticals INC | $518.65 | 2019-2025 | Nuplazid |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $507.87 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Adamas Pharmaceuticals, INC. | $504.17 | 2019-2021 | |
| Acorda Therapeutics, INC | $476.46 | 2019-2024 | Inbrija, Ampyra |
| Lundbeck LLC | $460.43 | 2019-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $453.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $414.79 | 2019-2022 | |
| Tanabe Pharma America, INC. | $405.26 | 2019-2024 | |
| Upsher-Smith Laboratories LLC | $392.04 | 2019-2022 | |
| Amgen INC. | $383.18 | 2019-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $328.40 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $304.96 | 2020-2021 | |
| Abbott Laboratories | $304.44 | 2023-2025 | Infinity |
| Kyowa Kirin, INC. | $262.74 | 2019-2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $227.88 | 2020-2023 | Ponvory |
| Genzyme Corporation | $227.45 | 2019-2023 | |
| Boston Scientific Corporation | $212.98 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $180.58 | 2019-2025 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Avion Pharmaceuticals | $160.83 | 2022-2023 | Dhivy |
| Idorsia Pharmaceuticals US INC | $138.60 | 2023-2024 | Quviviq |
| Ge Healthcare | $120.50 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $108.07 | 2019 | |
| Greenwich Biosciences, INC. | $100.98 | 2019-2020 | |
| Janssen Biotech, INC. | $90.44 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $82.60 | 2021-2024 | Wainua |
| Genentech USA, INC. | $74.60 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $72.26 | 2025 | Symbravo |
| Supernus Pharmaceuticals, INC. | $71.18 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $70.65 | 2022 | |
| Scilex Pharmaceuticals INC. | $66.80 | 2023-2024 | Ztlido |
| Neurelis, INC. | $64.58 | 2022-2024 | Valtoco |
| Merz Pharmaceuticals, LLC | $56.43 | 2023-2025 | Xeomin |
| Jazz Pharmaceuticals INC. | $53.56 | 2022 | |
| Alnylam Pharmaceuticals INC. | $52.58 | 2022-2023 | Onpattro |
| Livanova USA, INC. | $43.46 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Currax Pharmaceuticals LLC | $40.11 | 2020-2021 | |
| Horizon Therapeutics Plc | $39.72 | 2022-2023 | Uplizna |
| Averitas Pharma INC. | $39.55 | 2023 | Qutenza |
| Octapharma USA, INC. | $38.31 | 2023-2024 | Panzyga |
| Csl Behring | $21.98 | 2019 | |
| Grt US Holding, INC. | $18.94 | 2022 | |
| Corium, LLC | $17.05 | 2023 | Adlarity |
| Almatica Pharma LLC | $15.63 | 2023 | Gralise |
| Promius Pharma LLC | $15.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.92 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.54 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.